/
We are a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases, who have unmet medical needs. We use our protein engineering capabilities to design new technologies and XmAb drug candidates with improved properties and multi-target mechanisms of action.
The business is unprofitable at the operating level (-141.35% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 13.7% YoY with margins expanding 20.1pp.
Negative free cash flow of -$138M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$97M
▲ +13.7% YoY
Net Income (TTM)
-$172M
▲ +60.5% YoY
Op. Margin
-217.93%
▲ +20.1pp YoY
ROIC
-21.12%
▼ -0.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$189M
▲ +33.6% YoY
Op. Cash Flow (TTM)
-$187M
▲ +33.2% YoY
Net Debt
$161M
Cash & Equiv.
$14M
5Y CAGR: +0.5%
Continue Research